Trexquant Investment LP Has $1.69 Million Stock Holdings in Arcus Biosciences, Inc. $RCUS

Key Points

• Trexquant Investment LP has reduced its stake in Arcus Biosciences by 28.3%, selling 85,182 shares and holding 215,366 shares worth approximately $1.69 million.
• Other institutional investors made significant changes to their holdings, with Allspring Global Investments increasing their stake by 54.0%, reflecting growing interest in the company.
• Arcus Biosciences recently reported impressive earnings, generating $160 million in revenue for the quarter, a 310.3% increase year-over-year, despite a reported loss per share.

Trexquant Investment LP reduced its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 28.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,366 shares of the company's stock after selling 85,182 shares during the period. Trexquant Investment LP owned about 0.20% of Arcus Biosciences worth $1,691,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in Arcus Biosciences during the fourth quarter valued at $531,000. First Trust Advisors LP lifted its holdings in Arcus Biosciences by 43.1% in the 4th quarter. First Trust Advisors LP now owns 17,708 shares of the company's stock valued at $264,000 after acquiring an additional 5,337 shares during the last quarter. Voya Investment Management LLC lifted its holdings in Arcus Biosciences by 37.5% in the 4th quarter. Voya Investment Management LLC now owns 24,674 shares of the company's stock valued at $367,000 after acquiring an additional 6,733 shares during the last quarter. Northern Trust Corp lifted its stake in Arcus Biosciences by 4.3% during the fourth quarter. Northern Trust Corp now owns 532,099 shares of the company's stock valued at $7,923,000 after buying an additional 22,181 shares in the last quarter. Finally, Algert Global LLC lifted its stake in Arcus Biosciences by 59.6% during the fourth quarter. Algert Global LLC now owns 180,122 shares of the company's stock valued at $2,682,000 after buying an additional 67,275 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Wells Fargo & Company lowered their price target on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $21.14.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS traded up $0.43 during midday trading on Wednesday, reaching $11.75. The company's stock had a trading volume of 888,290 shares, compared to its average volume of 725,692. The business's fifty day simple moving average is $9.90 and its 200-day simple moving average is $9.15. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.50 and a quick ratio of 4.50. The company has a market capitalization of $1.25 billion, a P/E ratio of -3.71 and a beta of 0.83. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.The firm had revenue of $160.00 million during the quarter, compared to analyst estimates of $32.86 million. During the same period last year, the company earned ($1.02) earnings per share. The company's revenue was up 310.3% on a year-over-year basis. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.